Revolution Medicines, Inc.
RVMD
$37.01
$0.531.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 742.00K | 742.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 742.00K | 742.00K |
| Cost of Revenue | 564.72M | 558.37M | 470.64M | 419.13M | 375.11M |
| Gross Profit | -564.72M | -558.37M | -470.64M | -418.39M | -374.37M |
| SG&A Expenses | 127.77M | 108.90M | 96.72M | 87.15M | 78.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 897.50M | 789.43M | 689.52M | 628.44M | 575.98M |
| Operating Income | -897.50M | -789.43M | -689.52M | -627.70M | -575.23M |
| Income Before Tax | -812.81M | -698.26M | -600.85M | -566.72M | -522.73M |
| Income Tax Expenses | -753.00K | -753.00K | -753.00K | 343.00K | -3.52M |
| Earnings from Continuing Operations | -812.06 | -697.51 | -600.09 | -567.06 | -519.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -812.06M | -697.51M | -600.09M | -567.06M | -519.21M |
| EBIT | -897.50M | -789.43M | -689.52M | -627.70M | -575.23M |
| EBITDA | -890.70M | -782.75M | -683.00M | -621.56M | -569.47M |
| EPS Basic | -4.50 | -4.00 | -3.57 | -3.59 | -3.65 |
| Normalized Basic EPS | -2.82 | -2.50 | -2.23 | -2.13 | -2.19 |
| EPS Diluted | -4.50 | -4.00 | -3.57 | -3.59 | -3.65 |
| Normalized Diluted EPS | -2.82 | -2.50 | -2.23 | -2.13 | -2.19 |
| Average Basic Shares Outstanding | 717.33M | 693.89M | 670.47M | 637.90M | 580.29M |
| Average Diluted Shares Outstanding | 717.33M | 693.89M | 670.47M | 637.90M | 580.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |